이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
BioMarin Pharmaceutical 대차 대조표 상태
재무 상태 기준 확인 6/6
BioMarin Pharmaceutical 의 총 주주 지분은 $5.3B 이고 총 부채는 $1.1B, 이는 부채 대 자기자본 비율을 20.6% 로 가져옵니다. 총자산과 총부채는 각각 $7.1B 및 $1.8B 입니다. BioMarin Pharmaceutical 의 EBIT는 $243.0M 이며 이자보상배율은 -4.3 입니다. $1.2B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
20.6%
부채 비율
US$1.09b
부채
| 이자 보상 비율 | -4.3x |
| 현금 | US$1.22b |
| 주식 | US$5.29b |
| 총 부채 | US$1.78b |
| 총 자산 | US$7.07b |
최근 재무 상태 업데이트
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25Recent updates
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10재무 상태 분석
단기부채: BMRN 의 단기 자산 ( $3.3B )이 단기 부채( $1.1B ).
장기 부채: BMRN 의 단기 자산( $3.3B )이 장기 부채( $713.5M ).
부채 대 자본 내역 및 분석
부채 수준: BMRN 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: BMRN 의 부채 대 자기자본 비율은 지난 5년간 28.3% 에서 20.6% 로 감소했습니다.
부채 범위: BMRN 의 부채는 영업 현금 흐름 ( 25.8% )에 의해 잘 충당되었습니다.
이자 보장: BMRN 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.